Medexus
Medexus Pharmaceuticals is a publicly traded North American specialty pharmaceutical company developing and commercializing innovative orphan drug and rare disease products across allergy, dermatology, hematology, oncology, and rheumatology, serving healthcare professionals and patients through an integrated salesforce.
- Company typePublic
- Founded2000
- HeadquartersMississauga, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medexus does
Medexus Pharmaceuticals, Inc. is a North American specialty pharmaceutical company focused on innovative orphan drug and rare disease products. Incorporated in the United States and headquartered in Mississauga, Canada, the company is publicly traded under the ticker MDP and operates two regional product portfolios covering allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Its lead commercial asset, GRAFAPEX (treosulfan) for Injection, has been cited as a driver of continued strong product-level performance in fiscal Q3 and full-year 2026 results.
The company's core technology is a portfolio of specialty pharmaceutical products and, more recently, a novel personalized hematopoietic stem cell therapy (Zemcelpro® / dorocubicel / UM171 Cell Therapy) licensed from ExCellThera Inc. and Cordex Biologics for Canadian commercialization. Zemcelpro has received conditional marketing authorization from the European Commission, with Health Canada approval pending and Canadian commercialization not expected before calendar year 2028. The licensing structure provides Medexus with royalties on Canadian net sales and milestone payments tied to regulatory and commercialization milestones.
Medexus operates a sales-led go-to-market model through a fully integrated North American infrastructure encompassing commercial operations, supply chain, regulatory, medical affairs, and a direct salesforce targeting healthcare professionals and health systems. Revenue is generated from product sales of its specialty and rare disease portfolio and from licensing-related royalties and milestone payments on partnered assets. The company employs between 11 and 50 people, has no disclosed parent company, and markets itself primarily through its corporate website, investor relations channels, email alerts, and social media.
Medexus firmographics
Firmographics- Name
- Medexus
- Legal name
- Medexus Pharmaceuticals, Inc.
- Website
- https://medexus.ca
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Medexus Pharmaceuticals is a publicly traded North American specialty pharmaceutical company developing and commercializing innovative orphan drug and rare disease products across allergy, dermatology, hematology, oncology, and rheumatology, serving healthcare professionals and patients through an integrated salesforce.
- Ownership category
- akta.pro rank
Medexus industry classification
Industry- Product category
- Specialty Pharmaceuticals (Orphan Drug and Rare Disease)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where Medexus is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Markets served
Medexus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Product sales: Sale of specialty and rare disease pharmaceutical products including GRAFAPEX (treosulfan) for injection and other products in the portfolio addressing allergy, dermatology, hematology, oncology, and rheumatology.
- Royalties and milestone payments: Royalties on Canadian net sales of Zemcelpro® and milestone payments related to regulatory approvals and commercialization milestones for licensed products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Medexus product offering
Product offeringCore offering
Medexus Pharmaceuticals is a specialty and rare disease pharmaceutical company that develops, licenses, and commercializes innovative treatments across therapeutic areas including allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Its commercialized portfolio includes GRAFAPEX (treosulfan) for Injection and the recently licensed Zemcelpro® (UM171 Cell Therapy) for Canadian commercialization, distributed through a fully integrated North American sales and supply chain infrastructure.
Product overview
Medexus Pharmaceuticals, Inc. is a leading innovative orphan drug and rare disease pharmaceutical company with a North American business model. The company operates through two regional product portfolios (Canadian and US), featuring specialty pharmaceutical products for treating diseases including allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Key products include GRAFAPEX for Injection (treosulfan) and the recently licensed Zemcelpro® (UM171 Cell Therapy) for Canadian market. The company has an integrated infrastructure including commercial operations, supply chain, regulatory, medical affairs, and salesforce capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Zemcelpro® (dorocubicel/UM171 Cell Therapy) A novel personalized hematopoietic stem cell transplantation product for treating hematological malignancies. It received conditional marketing authorization from the European Commission; Canadian commercialization is pending Health Canada approval and not expected before calendar year 2028.
- GRAFAPEX (treosulfan) for Injection A specialty pharmaceutical injection product containing treosulfan, marketed to healthcare professionals for the treatment of hematological malignancies and related rare disease indications. Demonstrated strong product-level performance in fiscal Q3 and fiscal year 2026 results.
- Medexus Canadian Product Portfolio
- Medexus US Product Portfolio Medexus's U.S. product portfolio of specialty and rare disease products spanning allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Sold in the U.S. through the company's North American salesforce and commercial operations.
Companies that use Medexus
Customer profileSegments1 record
Ideal customer profiles1 record
Medexus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Medexus partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- ExCellThera Inc.coreExCellThera Inc. and its wholly owned subsidiary Cordex Biologics granted exclusive licensing and supply agreements to Medexus for Canadian commercialization rights for Zemcelpro® (dorocubicel/UM171 Cell Therapy). The product is a novel personalized hematopoietic stem cell transplantation product for treating hematological malignancies. Cordex continues to manage the clinical program and manufacturing supply. Transaction includes royalties on Canadian net sales and milestone payments.
- Cordex BiologicscoreWholly owned subsidiary of ExCellThera Inc. that manages the clinical program and manufacturing supply for Zemcelpro® (UM171 Cell Therapy). Continues to supply the product while Medexus holds Canadian commercialization rights.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Medexus competitors and assessment
Company assessmentBroad incumbents
- Astellas Pharma (Rare Disease / Xtandi franchise): Global pharma with a significant specialty hematology/oncology franchise and rare disease ambitions; comparable as a broader incumbent overlapping in therapeutic areas Medexus targets.
- Alexion / AstraZeneca Rare Disease: Established rare disease specialist within a major pharma, competing in the same hematology and rare oncology indications as Medexus's portfolio and representing the strategic exit benchmark for specialty rare disease assets.
- Bausch Health Companies: Diversified specialty pharma with branded specialty products in dermatology, oncology, and other therapeutic areas overlapping with Medexus's portfolio.
Direct peers
- Pacira BioSciences: Specialty pharma commercializing differentiated products (e.g., injectables) through a focused North American specialty salesforce, similar to Medexus's GRAFAPEX-style injectable specialty model.
- Jazz Pharmaceuticals: Specialty pharmaceutical company with a strong rare disease and hematology/oncology portfolio; most comparable in commercial model targeting specialty physicians and in therapeutic focus on hematological malignancies.
- Mallinckrodt plc: Specialty pharma with branded specialty and rare disease products distributed through a specialty salesforce, overlapping with Medexus's model of in-licensed specialty assets commercialized in North America.
- Recordati Rare Diseases: Focused exclusively on rare disease specialty pharmaceuticals across multiple therapeutic areas, closely matching Medexus's orphan-drug positioning and portfolio diversification strategy.
- Helsinn Group: Specialty pharma focused on oncology and rare disease supportive care, with licensing-led commercial models similar to Medexus's strategy of in-licensing specialty assets for North America.
Emerging players
- Verastem Oncology: Small-cap oncology-focused specialty company commercializing hematology/oncology products through targeted sales efforts, with similar therapeutic overlap to Medexus's rare oncology portfolio.
- Apellis Pharmaceuticals: Emerging specialty/biopharma with rare disease ophthalmology and hematology assets commercialized via specialty channels, comparable in scale and go-to-market model to Medexus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Medexus social profiles
Digital presenceMedexus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medexus leadership team
Management profileNumber of profiles
Profiles1 record
Medexus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medexus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medexus
What does Medexus do?
Medexus Pharmaceuticals is a specialty and rare disease pharmaceutical company that develops, licenses, and commercializes innovative treatments across therapeutic areas including allergy, dermatology, hematology (rare disease), oncology (rare disease), and rheumatology. Its commercialized portfolio includes GRAFAPEX (treosulfan) for Injection and the recently licensed Zemcelpro® (UM171 Cell Therapy) for Canadian commercialization, distributed through a fully integrated North American sales and supply chain infrastructure.
Is Medexus a public or private company?
Medexus is a public company. It is classified as public and is currently operating.
When was Medexus founded?
Medexus was founded in 2000. It employs 11 to 50 people.
Where is Medexus based?
Medexus is headquartered in Mississauga, Canada, in the North America region.
How does Medexus make money?
Two revenue lines are on record. Product sales are the primary driver. The others are royalties and milestone payments.
Who are Medexus's main competitors?
Broad incumbents on record are Astellas Pharma (Rare Disease / Xtandi franchise), Alexion / AstraZeneca Rare Disease and Bausch Health Companies. Direct peers are Pacira BioSciences, Jazz Pharmaceuticals, Mallinckrodt plc, Recordati Rare Diseases and Helsinn Group. Emerging players are Verastem Oncology and Apellis Pharmaceuticals.
Does Medexus have an API?
No public API is recorded for Medexus.
What industry is Medexus in?
Medexus's product category is Specialty Pharmaceuticals (Orphan Drug and Rare Disease). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAIAC, Rare Oncology & Hematologic Malignancy Therapies. Its NAICS code is 325412 and its SIC code is 2834.